Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Primary central nervous system tumors are the most common solid neoplasm of childhood and the leading cause of cancer-related death in pediatric patients. Survival rates for children with malignant supratentorial brain tumors are poor despite aggressive treatment with combinations of surgery, radiation, and chemotherapy, and survivors often suffer from damaging lifelong sequelae from current therapies. Novel innovative treatments are greatly needed. One promising new approach is the use of a genetically engineered, conditionally replicating herpes simplex virus (HSV) that has shown tumor-specific tropism and potential efficacy in the treatment of malignant brain tumors. G207 is a genetically engineered HSV-1 lacking genes essential for replication in normal brain cells. Safety has been established in preclinical investigations involving intracranial inoculation in the highly HSV-sensitive owl monkey (Aotus nancymai), and in three adult phase 1 trials in recurrent/progressive high-grade gliomas. No dose-limiting toxicities were seen in the adult studies and a maximum tolerated dose was not reached. Approximately half of the 35 treated adults had radiographic or neuropathologic evidence of response at a minimum of one time point. Preclinical studies in pediatric brain tumor models indicate that a variety of pediatric tumor types are highly sensitive to killing by G207. This clinical protocol outlines a first in human children study of intratumoral inoculation of an oncolytic virus via catheters placed directly into recurrent or progressive supratentorial malignant tumors.
1 Department of Surgery, Division of Pediatric Surgery, University of Alabama at Birmingham , Birmingham, Alabama.
Alicia M
AM
Waters
2 Department of Neurosurgery, University of Alabama at Birmingham , Birmingham, Alabama.
James M
JM
Johnston
3 Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham , Birmingham, Alabama.
Alyssa T
AT
Reddy
4 Department of Radiation Oncology, University of Alabama at Birmingham , Birmingham, Alabama.
John
J
Fiveash
3 Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham , Birmingham, Alabama.
Avi
A
Madan-Swain
5 Division of Hematology/Oncology, Children's of Alabama , Birmingham, Alabama.
Kara
K
Kachurak
6 Department of Radiology, University of Alabama at Birmingham , Birmingham, Alabama.
Asim K
AK
Bag
2 Department of Neurosurgery, University of Alabama at Birmingham , Birmingham, Alabama.
G Yancey
GY
Gillespie
2 Department of Neurosurgery, University of Alabama at Birmingham , Birmingham, Alabama.|3 Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham , Birmingham, Alabama.
James M
JM
Markert
3 Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham , Birmingham, Alabama.
Gregory K
GK
Friedman
D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000235:genetics / Q000532:radiotherapy / Q000821:virology; D002648:Child; D002675:Child, Preschool; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage*; D018259:Herpesvirus 1, Human / Q000235:genetics*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000532:radiotherapy / Q000821:virology; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics; D012107:Research Design; D012449:Safety; D015173:Supratentorial Neoplasms / Q000235:genetics* / Q000532:radiotherapy* / Q000821:virology
G207; HSV; brain tumors; oncolytic; pediatric; virotherapy